Fight Over Waze? Way
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$77.76 -0.72 | -0.92%
05/24/13 - 12:30 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 1.53B | 1.41B | 143.37M | 101.89M |
| Cost of Sales | 241.69M | 27.06M | 12.73M | -19.03M |
| Gross Operating Profit | 1.29B | 1.38B | 130.64M | 120.92M |
| Selling, General, and Administrative Expenses | 436.80M | 400.72M | 187.80M | 130.19M |
| Research & Development | 806.18M | 707.71M | 637.42M | 550.27M |
| Operating Income before D & A (EBITDA) | 42.37M | 275.14M | -694.58M | -559.55M |
| Depreciation & Amortization | 38.19M | 53.45M | 44.05M | 33.23M |
| Interest Income | 1.94M | 1.88M | 1.96M | 5.01M |
| Other Income - Net | 0.00 | -16.80M | -41.23M | -27.78M |
| Special Income / Charges | 0.00 | -105.80M | 0.00 | -7.20M |
| Total Income Before Interest Expenses (EBIT) | 4.27M | 98.90M | -779.40M | -628.99M |
| Interest Expense | 16.65M | 38.45M | 19.28M | 13.19M |
| Pre-Tax Income | -12.38M | 60.44M | -798.67M | -642.18M |
| Income Taxes | 38.75M | 19.27M | 0.00 | 0.00 |
| Minority Interest | 55.90M | 11.60M | 0.00 | 0.00 |
| Net Income From Continuing Operations | -51.14M | 29.57M | -754.63M | -642.18M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -51.14M | 29.57M | -754.63M | -642.18M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -107.03M | 29.57M | -754.63M | -642.18M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-49.29M | 137.45M | -753.12M | -628.74M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -51.14M | 29.57M | -754.63M | -642.18M |
| Basic EPS from Continuing Ops. | -0.50 | 0.14 | -3.77 | -3.71 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.50 | 0.14 | -3.77 | -3.71 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.50 | 0.14 | -3.77 | -3.71 |
| Basic Normalized Net Income/Share | -0.48 | 0.65 | -3.76 | -3.63 |
| EPS fr Continuing Ops. | -0.50 | 0.14 | -3.77 | -3.71 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.50 | 0.14 | -3.77 | -3.71 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.50 | 0.14 | -3.77 | -3.71 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.48 | 0.65 | -3.76 | -3.63 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with VRTX
- Portfolio NameUser Type
- UserDC
- UserPortfolio
- ProDaniel Loeb - Third Point
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- ContributorEarnings Short Squeeze Play...
- Contributor10 Hep C Stocks on Wall Str...
Latest VRTX Headlines from TheStreet
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard 05.16.13 | 05:05 pm
- 3 Stocks Underperforming Today In The Drugs Industry 05.15.13 | 01:05 pm
- 3 Stocks Improving Performance Of The Health Care Sector 05.06.13 | 01:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 05.03.13 | 05:05 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard 04.26.13 | 05:04 pm
- Vertex CFO Rings Register On $35 Million Insider Sale 04.24.13 | 07:04 am
- 'Mad Money' Lightning Round: Apache Is a Dog 04.24.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Looking for Winners in Unlikely Places 04.23.13 | 08:04 pm
- 4 Stocks Pushing The Drugs Industry Downward 04.22.13 | 01:04 pm
Press Releases for VRTX
- VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study - Business Wire 03.04.13 | 08:03 am
- Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences - Business Wire 02.27.13 | 04:02 pm
- Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 02.26.13 | 04:02 pm
- Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 02.01.13 | 12:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs - Business Wire 01.29.13 | 04:01 pm
- Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29 - Business Wire 01.15.13 | 04:01 pm
- Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities - Business Wire 01.06.13 | 05:01 pm
- NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 12.19.12 | 09:12 am
- Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir) - Business Wire 12.19.12 | 08:12 am
- Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D) - Business Wire 12.03.12 | 08:12 am
Partner Headlines for VRTX
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Inside Wall Street: closer to a cystic fibrosis cure - MSN Money 05.03.13 | 01:05 pm
- Gilead's HCV Drug Pipeline Outshines Weak Q1 Results - Investor's Business Daily 05.02.13 | 06:05 pm
- Stocks Down In Rising Trade; Nuance Communications Falls - Investor's Business Daily 04.30.13 | 10:04 am
- Vertex Pharmaceuticals Earnings: Here’s Why Shares are Up Now - Wall St. Cheat Sheet 04.30.13 | 06:04 am
- Vertex Pharmaceuticals Incorporated Earnings Preview: Can This Streak Finally End? - Wall St. Cheat Sheet 04.29.13 | 11:04 am
- Weekly Preview: Focus Shifts from Earnings to Economy - Benzinga 04.26.13 | 04:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,233.55 up 27.49 points - NASDAQ 04.22.13 | 08:04 pm
- Stocks Improve Late Session; Dow Industrials Turn Green - Investor's Business Daily 04.22.13 | 02:04 pm
- Biotech Stocks Get A Turbo Boost From Vertex - Seeking Alpha 04.20.13 | 09:04 am
